<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stiff skin syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stiff skin syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Stiff skin syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie Powell, MD, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jérôme Coulombe, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3227715649"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Stiff skin syndrome (SSS; MIM #184900) is a rare, noninflammatory, scleroderma-like disorder with onset usually in infancy or childhood. First described in 1971 [<a href="#rid1">1</a>], SSS<strong> </strong>is characterized by areas of stony-hard skin involving the trunk and extremities; joint contractures; decreased joint mobility, mainly involving the pelvic and shoulder girdles; and a slow, progressive course. A less severe, segmental variant has also been described [<a href="#rid2">2</a>]. Options for treatment are limited, and response is often unsatisfactory.</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and management of SSS. Pediatric systemic sclerosis and localized scleroderma (morphea) and other pediatric, scleroderma-like entities are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">"Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6399.html" rel="external">"Juvenile localized scleroderma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/89274.html" rel="external">"Scleredema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13737.html" rel="external">"Sclerema neonatorum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/106741.html" rel="external">"Hutchinson-Gilford progeria syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H9192120"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>SSS is exceedingly rare. Approximately 100 cases have been described in the literature [<a href="#rid2">2,3</a>]. All cases, except one, had a pediatric onset [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H1727644406"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Heterozygous, missense variants in the fibrillin-1 (<em>FBN1</em>) gene<strong> </strong>have been shown to cause SSS [<a href="#rid5">5</a>]. The FBN1 protein is the major component of the 10 to 12 nm extracellular matrix microfibrils, which provide tissues with structural support and frame for elastin deposition. FBN1 contains many cysteine-rich domains homologous to the epidermal growth factor (EGF) and the latent transforming growth factor (TGF)-beta binding proteins. The latter is a family of profibrotic cytokines involved in the pathogenesis of several fibrotic diseases, including SSS and systemic sclerosis [<a href="#rid5">5,6</a>].</p><p>Variants affecting the TB4 domain of FBN1 cause impaired TGF-beta signaling, elevated TGF-beta concentration in the skin, impaired elastogenesis, excessive microfibrillar deposition, and ultimately unregulated skin fibrosis. This results in skin tightening, joint stiffness, immobilization, and progressive limitation of the range of motion of joints and thoracic walls [<a href="#rid6">6-8</a>].</p><p><em>FBN1</em> variants affecting different domains of FBN1 are associated with different phenotypes. As an example, variants affecting the TB5 domain of FBN1 cause the much more common Marfan syndrome. (See  <a class="medical medical_review" href="/z/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>.)</p><p>The pathogenesis of segmental SSS is uncertain. It is probably a mosaic subtype of SSS, although somatic <em>FBN1</em> variants have not been demonstrated in lesional skin. A case report has shown the possible implication of variants in interleukin (IL) 17 gene [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H2120014769"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Two clinical subtypes of SSS, widespread SSS and segmental SSS, have been described [<a href="#rid2">2,10</a>]. They are distinguished by the distribution of skin lesions, time of onset, and severity of musculoskeletal involvement.</p><p class="headingAnchor" id="H2892917803"><span class="h2">Widespread stiff skin syndrome</span><span class="headingEndMark"> — </span>Widespread SSS is the most common type. It presents insidiously during infancy or early childhood and can be quite subtle at first. "Congenital fascial dystrophy" is considered a subset of SSS with predominant fascial involvement and less severe skin tightening [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous features</strong> – Progressive, bilateral skin induration overlying areas with abundant fascia, such as the buttocks and thighs [<a href="#rid11">11</a>], results in rock-hard skin that is firmly bound to the underlying tissues without a groove sign  (<a class="graphic graphic_picture graphicRef133168 graphicRef134190" href="/z/d/graphic/133168.html" rel="external">picture 1A-B</a>). Skin can be normal appearing or mildly hyperpigmented. Mild hypertrichosis is noted over the affected areas in approximately one-third of cases. Pelvic and shoulder girdle areas are primarily involved [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracutaneous features</strong> – Ongoing skin induration leads to contractures of the large joints over months to years following disease onset, resulting in scoliosis, lordotic stance, and tiptoe gait [<a href="#rid10">10</a>]. Chronic exertional compartment syndrome requiring bilateral fasciotomy has been described in a father and son with bilateral lower limb pain and neurologic symptoms on exertion [<a href="#rid12">12</a>]. Severe cases can evolve to chest wall deformities, restrictive ventilatory defect, and growth retardation resulting in short stature. Neck mobility, chest wall deformities, and veinous access should be carefully evaluated preoperatively by an anesthesiologist to minimize complications [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">"Chest wall diseases and restrictive physiology"</a>.)</p><p></p><p class="bulletIndent1">Unlike systemic sclerosis or localized scleroderma, SSS is not accompanied by muscular, vascular, or internal organ involvement [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H4218285054"><span class="h2">Segmental stiff skin syndrome</span><span class="headingEndMark"> — </span>Segmental SSS is a less common or recognized form of SSS, with onset in childhood or early adolescence [<a href="#rid2">2,15</a>]. It presents with similar cutaneous and extracutaneous features as the widespread form but in a less severe fashion. Lesions are typically distributed unilaterally  (<a class="graphic graphic_picture graphicRef133167" href="/z/d/graphic/133167.html" rel="external">picture 2</a>) and result in joint contractures and mobility limitation in less than one-half of cases [<a href="#rid2">2</a>]. However, the involvement of large joints can cause significant morbidity [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1871486671"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Both widespread SSS and segmental SSS show similar histopathologic features. The epidermis is normal. The dermis shows horizontally oriented, thickened collagen bundles; increased mucin; and lack of inflammatory infiltrate and adnexal entrapment  (<a class="graphic graphic_picture graphicRef133169" href="/z/d/graphic/133169.html" rel="external">picture 3</a>). Adipocyte entrapment by thickened collagen bundles in the reticular dermis and subcutaneous septa, resulting in a bland, hamartomatous appearance, is a hallmark of SSS  (<a class="graphic graphic_picture graphicRef133170" href="/z/d/graphic/133170.html" rel="external">picture 4</a>). Fibroblast density is usually normal but can be elevated in some patients [<a href="#rid16">16</a>]. In biopsies that include fascia, noninflammatory sclerosis and thickening of the fascia can be noted [<a href="#rid2">2,10,17,18</a>].</p><p class="headingAnchor" id="H1480812369"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>There are no defined diagnostic criteria for widespread SSS and segmental SSS. Patients are often initially diagnosed with systemic sclerosis, localized scleroderma, or other scleroderma-like disorders. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Patient history, physical examination, skin biopsy and careful clinicopathologic correlation, exclusion of disease mimickers, lack of response to anti-inflammatory therapies, and a high index of suspicion contribute to the diagnosis of SSS [<a href="#rid2">2,10</a>]. Genetic testing for variants of <em>FBN1</em>, if available, can confirm the diagnosis in patients with the widespread form:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient history </strong>– Patients with SSS typically have a history of insidious onset of painless, progressive, bilateral skin induration, with onset in infancy or childhood and predominantly involving areas with abundant fascia, like the shoulders and pelvic girdles. Family history can be positive in patients with widespread SSS but is always negative in patients with the segmental form.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination </strong>– A total body skin examination should be performed to assess the location and extent of indurated areas bound to underlying tissues; the presence of cutaneous inflammation or other findings associated with systemic or localized sclerosis (eg, Raynaud phenomenon, acral sclerosis, "groove sign" [area of depression at sites with underlying tendons and ligaments]); and the gentle extension of the large joints for flexion contracture. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy </strong>– A deep, elliptical skin biopsy of a recently involved area, which includes the epidermis, dermis, subcutis, and, when possible, fascia, provides an adequate specimen for histopathologic examination. Routine stains, including mucin coloration and fibroblast markers, are recommended. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests </strong>– Complete blood cell count, sedimentation rate, C-reactive protein, urinalysis, creatinine, electrolytes, creatine kinase, thyroid-stimulating hormone, antinuclear antibodies, extractable nuclear antigen antibodies panel, and rheumatoid factor are performed to rule out inflammatory and immune-mediated diseases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging studies </strong>– Imaging studies, including plain radiography, ultrasonography, and magnetic resonance imaging (MRI), can be used to assess joint contractures, skeletal deformities, and skin and fascia thickness and to rule out muscle and bone involvement that would suggest other diseases [<a href="#rid19">19</a>]. Ultrasound and MRI<em> </em>can also be used to monitor disease progression and response to treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – The identification of germline pathogenic variants in <em>FBN1</em> by DNA sequencing can confirm the diagnosis of widespread SSS, when available [<a href="#rid5">5</a>]. Testing a biopsy of affected skin for somatic variants in <em>FBN1</em> or other putative genes might be useful in segmental SSS.</p><p></p><p class="headingAnchor" id="H4114618588"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic sclerosis/scleroderma</strong> – Systemic sclerosis is rare in children and presents with characteristic progressive, acral, and digital skin sclerosis; arthritis; internal organ involvement (lungs, kidneys); vascular changes (nailfold capillary changes, Raynaud phenomenon); and positive immunologic and inflammatory markers (scleroderma-specific antinuclear antibodies). (See  <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">"Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic fasciitis</strong> – Eosinophilic fasciitis is rare in children and typically affects middle-aged adults with a male predominance. It is characterized by acute onset of symmetric erythema, swelling, and woody skin induration of the extremities (forearm, calf) [<a href="#rid19">19</a>]. Skin changes include orange peel appearance and "groove signs"  (<a class="graphic graphic_picture graphicRef98466" href="/z/d/graphic/98466.html" rel="external">picture 5</a>). Blood eosinophils and inflammatory markers are elevated. (See  <a class="medical medical_review" href="/z/d/html/7547.html" rel="external">"Eosinophilic fasciitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized scleroderma (morphea)</strong> – Linear scleroderma and deep morphea beginning in childhood can be difficult to differentiate clinically from segmental SSS  (<a class="graphic graphic_picture graphicRef78212" href="/z/d/graphic/78212.html" rel="external">picture 6</a>). Localized scleroderma typically shows absence of adnexa, whereas SSS can be associated with hypertrichosis. On histopathology, localized scleroderma shows inflammatory infiltrates in the dermis with adnexal entrapment, without adipocyte entrapment, and occasional fascial inflammation. Localized scleroderma will typically show a positive response to immunosuppressive therapy, whereas widespread SSS and segmental SSS do not [<a href="#rid10">10,20,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/6399.html" rel="external">"Juvenile localized scleroderma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scleredema</strong> – Scleredema is a rare condition that occurs more frequently in adults. In children, it typically follows a streptococcal infection of the upper respiratory tract. Scleredema presents acutely with induration of the skin of the face or neck, occasionally spreading downwards to the shoulders, arms, back, and chest  (<a class="graphic graphic_picture graphicRef90965" href="/z/d/graphic/90965.html" rel="external">picture 7</a>). Histology shows broad collagen bundles and dermal mucin deposits. Involvement of the fascia is absent. It can be differentiated from SSS by the abrupt onset, different body locations involved, and histopathology [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/89274.html" rel="external">"Scleredema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare pediatric entities</strong> – Several other rare conditions can be included in the differential diagnosis of SSS [<a href="#rid10">10</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyaline fibromatosis syndrome</strong> – Hyaline fibromatosis syndrome (MIM #228600),<strong> </strong>which includes infantile systemic hyalinosis and juvenile hyaline fibromatosis, is an exceedingly rare, autosomal recessive disorder characterized by hyaline deposits in the papillary dermis and other tissues [<a href="#rid22">22</a>]. It presents in infancy with papules around the nose and mouth; gingival hypertrophy; thickened, firm skin; hyperpigmented patches over the joints; progressive joint contractures; and severe pain with movements. Hyaline fibromatosis syndrome is caused by biallelic pathogenic variants in <em>ANTXR2</em>, encoding the anthrax toxin receptor 2.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mucopolysaccharidoses</strong> – The mucopolysaccharidoses are a group of rare, inherited lysosomal diseases with a broad phenotypic spectrum caused by deficiency of enzymes involved in the breakdown of glycosaminoglycans. Mucopolysaccharidoses present in infancy or early childhood with focal skin thickening with a pebbled surface, coarse facial features, hepatosplenomegaly, bone disease, and with or without intellectual disability. The diagnosis is based on measurement of urinary mucopolysaccharides and enzyme activity in peripheral blood leucocytes and genetic testing. (See  <a class="medical medical_review" href="/z/d/html/2931.html" rel="external">"Mucopolysaccharidoses: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Restrictive dermopathy</strong> – Restrictive dermopathy (MIM #275210) is a rare, lethal genodermatosis characterized by abnormally tight skin from birth  (<a class="graphic graphic_picture graphicRef112139 graphicRef110284" href="/z/d/graphic/112139.html" rel="external">picture 8A-B</a>). Joint contractures; ectropion; chest wall narrowing; hypoplastic clavicles; and a fixed, O-shaped mouth are additional findings. A skin biopsy shows flattened rete ridges, a thin dermis with horizontally oriented collagen, and incompletely developed skin appendages. In most cases, restrictive dermopathy is caused by autosomal recessive variants in <em>ZMPSTE24</em>, encoding a zinc metalloproteinase involved in the post-translational processing of lamin A precursor [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sclerema neonatorum</strong> – Sclerema neonatorum is a severe and often fatal panniculitis that develops in severely ill, premature neonates. The skin is thickened, adherent to underlying tissues, and can symmetrically involve the subcutaneous fat of the entire body. (See  <a class="medical medical_review" href="/z/d/html/13737.html" rel="external">"Sclerema neonatorum"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hutchinson-Gilford progeria syndrome</strong> – Skin changes in Hutchinson-Gilford progeria syndrome (MIM #176670), a very rare, autosomal dominant, premature aging disorder that manifests in childhood, include atrophy, sclerotic skin areas, reticulate hyperpigmentation, dimpling, and mottling, especially on the abdomen and thighs. Additional findings include a characteristic facial appearance, alopecia and prominent scalp veins, and joint contractures. (See  <a class="medical medical_review" href="/z/d/html/106741.html" rel="external">"Hutchinson-Gilford progeria syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subcutaneous fat necrosis of the newborn</strong> – Subcutaneous fat necrosis of the newborn is a self-limited panniculitis that most often affects full-term newborns and presents with erythematous nodules or indurated plaques on the cheeks, back, buttocks, or proximal extremities  (<a class="graphic graphic_picture graphicRef112136" href="/z/d/graphic/112136.html" rel="external">picture 9</a>). (See  <a class="medical medical_review" href="/z/d/html/13738.html" rel="external">"Subcutaneous fat necrosis of the newborn"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extra-abdominal desmoid tumor fibromatosis</strong> – Extra-abdominal desmoid tumor fibromatosis is a rare, locally aggressive soft tissue tumor resulting from a monoclonal proliferation of fibroblasts. Extra-abdominal desmoid tumor fibromatoses are, in most cases, located in the abdominal wall, buttocks, trunk, and extremities and are associated with pain, contractures, and functional impairment. (See  <a class="medical medical_review" href="/z/d/html/7746.html" rel="external">"Desmoid tumors: Epidemiology, molecular pathogenesis, clinical presentation, diagnosis, and local therapy"</a>.)</p><p></p><p class="headingAnchor" id="H3512852556"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>All pediatric patients with suspected or confirmed diagnosis of widespread SSS or segmental SSS should be referred to a clinician who is part of a multidisciplinary team (including pediatric rheumatology and dermatology) experienced in the diagnosis and management of this disorder. Ideally, this team should be an integral part of a tertiary pediatric facility with access to subspecialists and services (eg, orthopedic surgery, physical therapy, orthotics service, medical genetics).</p><p class="headingAnchor" id="H3667884046"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There are no curative treatments for SSS. The progressive and relentless nature of SSS and its minimal response to topical and systemic treatments are a challenge for patients, caregivers, and clinicians. Management primarily includes an exercise schedule to maintain functional ability and psychologic and social support.</p><p class="headingAnchor" id="H3593420712"><span class="h2">Physical therapy</span><span class="headingEndMark"> — </span>A carefully designed treatment program, including physiotherapy and massage, is beneficial for many children with SSS and should be started early. Physiotherapy maintains functional ability, muscle strength, and joint movement while preventing flexion contractures [<a href="#rid24">24</a>]. The use of corrective splints and gait analysis may also be helpful. Attention to positive joint alignment and muscle development is particularly important.</p><p class="headingAnchor" id="H732054226"><span class="h2">Pharmacologic therapy</span><span class="headingEndMark"> — </span>Several pharmacologic agents, including systemic glucocorticoids, immunosuppressants, and drugs with antifibrotic or anti-transforming growth factor (TGF)-beta activity, have been tried in a few patients with SSS, in most cases with disappointing results [<a href="#rid25">25-28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Losartan</strong> – <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">Losartan</a>, an angiotensin II receptor antagonist, is known to have anti-TGF-beta activity in vitro [<a href="#rid7">7,29</a>]. It has been used in adult and pediatric patients with Marfan syndrome and has a favorable safety profile in patients with normal renal function [<a href="#rid30">30,31</a>]. In a single case report, oral losartan 0.7 mg/kg per day gradually increased up to 50 mg per day for two years induced mild improvement of skin tightening in a child with segmental SSS [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppressive agents </strong>– <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil is an immunosuppressive drug with antifibrotic properties [<a href="#rid32">32</a>]. In one report, mycophenolate mofetil 2 to 3 g per day for six months in combination with physical therapy induced mild improvement in skin induration and joint mobility in two young adult patients with segmental SSS [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">Oral <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a>, intravenous pulse <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and intravenous immunoglobulins have been tried with no or minimal improvement in a few patients with segmental SSS [<a href="#rid10">10,25,27</a>]. Some of these patients were initially diagnosed with localized scleroderma. Nonresponse to these therapies prompted diagnostic re-evaluation, leading to a final diagnosis of SSS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic agents </strong>– In one case report, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, an anti-interleukin (IL) 17A antibody, given subcutaneously at the dose of 150 mg every four weeks for four months halted disease progression and increased the skin softness in an adolescent patient with segmental SSS [<a href="#rid9">9</a>]. The choice of an anti-IL-17 agent was based on the identification of a novel IL-17 mutation in the patient and their family. In another case report, one-year treatment with secukinumab 300 mg every four weeks halted disease progression and induced slight skin softening and complete pain resolution in a 17-year-old patient with segmental SSS [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">There is no evidence that <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> or other biologic agents may be helpful in patients with SSS a<em>nd FBN1</em> gene mutations.</p><p></p><p class="headingAnchor" id="H4118922679"><span class="h2">Management of complications</span><span class="headingEndMark"> — </span>Consultation with multiple specialists may be needed to manage complications of widespread SSS and segmental SSS:</p><p class="bulletIndent1"><span class="glyph">●</span>Orthopedic surgeon for scoliosis management</p><p class="bulletIndent1"><span class="glyph">●</span>Orthotist for gait abnormality management</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory therapist and pulmonologist for severe, restrictive pneumopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Anesthesiologist for preoperative evaluation of airway, venous access, and restrictive pneumopathy</p><p></p><p class="headingAnchor" id="H1635068883"><span class="h1">DISEASE COURSE AND PROGNOSIS</span><span class="headingEndMark"> — </span>SSS is a nonfatal disorder that can cause major disability. It progresses gradually during the first years of life with contractures of the large joints, scoliosis, and gait anomalies. These complications are milder in the segmental form. There is no visceral involvement; however, chest wall deformities may cause a ventilatory, restrictive defect. (See  <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">"Chest wall diseases and restrictive physiology"</a>.) </p><p class="headingAnchor" id="H814843235"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Because of the gradual progression of the disease, periodic clinical follow-up should be performed, especially during the first years after the initial diagnosis. Evaluation of the extent of skin and joint involvement, mobility limitations, and physical therapy update are indicated.</p><p class="headingAnchor" id="H1034163862"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/131779.html" rel="external">"Society guideline links: Morphea (localized scleroderma)"</a>.)</p><p class="headingAnchor" id="H3526888366"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis</strong> – Stiff skin syndrome (SSS) is an exceedingly rare, noninflammatory, scleroderma-like condition with onset during infancy or childhood. The widespread variant is caused by autosomal dominant, missense variants in the fibrillin-1 (<em>FBN1</em>) gene, encoding the FBN1 protein, a major component of the extracellular matrix microfibrils.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Widespread SSS presents in infancy or early childhood with progressive, bilateral skin induration primarily involving the pelvic and shoulder girdle areas. Later complications include contractures of the large joints with reduced mobility, scoliosis, chest wall deformities, and tiptoe gait. Segmental SSS begins later in childhood or early adolescence, is usually unilateral, and is less severe. Skin induration is unilaterally distributed and less severe than the widespread form, and less frequently results in joint contractures. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of SSS is made based on patient history, clinicopathologic correlation, exclusion of disease mimickers, lack of response to anti-inflammatory therapies, and a high index of suspicion (see <a class="local">'Diagnosis'</a> above). Genetic testing for variants of <em>FBN1</em>, if available, can confirm the diagnosis in patients with widespread SSS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral</strong> – All pediatric patients with suspected or confirmed SSS should be referred to a clinician who is part of a multidisciplinary team (including pediatric rheumatology and dermatology) experienced in the diagnosis and management of this disorder, with access to subspecialists and services (eg, orthopedic surgery, physical therapy, orthotics service, medical genetics).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There are no curative therapies for SSS. Physical therapy to maintain functional ability, muscle strength, and joint movement and to prevent flexion contractures is of primary importance. Systemic glucocorticoids and other immunosuppressants are generally ineffective and do not alter disease progression. Oral <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a>, an angiotensin II receptor antagonist known to have anti-transforming growth factor (TGF)-beta activity, and <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> have been used in a limited number of patients, resulting in mild improvement of skin induration. (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Esterly NB, McKusick VA. Stiff skin syndrome. Pediatrics 1971; 47:360.</a></li><li><a class="nounderline abstract_t">Myers KL, Mir A, Schaffer JV, et al. Segmental stiff skin syndrome (SSS): A distinct clinical entity. J Am Acad Dermatol 2016; 75:163.</a></li><li><a class="nounderline abstract_t">Cerejeira D, Bonito F, António AM, Cunha H. Segmental stiff skin syndrome (SSS): Clinical case and a brief review. Australas J Dermatol 2021; 62:380.</a></li><li><a class="nounderline abstract_t">Sari A, Çirakoglu D. Middle-Aged Female Diagnosed With Widespread Stiff Skin Syndrome. Arch Rheumatol 2018; 33:491.</a></li><li><a class="nounderline abstract_t">Loeys BL, Gerber EE, Riegert-Johnson D, et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med 2010; 2:23ra20.</a></li><li><a class="nounderline abstract_t">Jensen SA, Iqbal S, Bulsiewicz A, Handford PA. A microfibril assembly assay identifies different mechanisms of dominance underlying Marfan syndrome, stiff skin syndrome and acromelic dysplasias. Hum Mol Genet 2015; 24:4454.</a></li><li><a class="nounderline abstract_t">Fusco C, Nardella G, Augello B, et al. Pro-Fibrotic Phenotype in a Patient with Segmental Stiff Skin Syndrome via TGF-β Signaling Overactivation. Int J Mol Sci 2020; 21.</a></li><li><a class="nounderline abstract_t">Del Cid JS, Reed NI, Molnar K, et al. A disease-associated mutation in fibrillin-1 differentially regulates integrin-mediated cell adhesion. J Biol Chem 2019; 294:18232.</a></li><li><a class="nounderline abstract_t">Rangu S, Rubin AI, Li D, Castelo-Soccio L. Segmental stiff skin syndrome: a novel case with an interleukin-17C mutation successfully treated with secukinumab. Clin Exp Dermatol 2020; 45:658.</a></li><li><a class="nounderline abstract_t">Liu T, McCalmont TH, Frieden IJ, et al. The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature. Arch Dermatol 2008; 144:1351.</a></li><li><a class="nounderline abstract_t">Jablonska S, Schubert H, Kikuchi I. Congenital fascial dystrophy: stiff skin syndrome--a human counterpart of the tight-skin mouse. J Am Acad Dermatol 1989; 21:943.</a></li><li><a class="nounderline abstract_t">Frecentese GI, Roche AD, Cederna PS. Chronic Exertional Compartment Syndrome Requiring Bilateral Fasciotomy: An Atypical Complication of Familial Stiff Skin Syndrome in a Father and Son. Ann Plast Surg 2023; 90:631.</a></li><li><a class="nounderline abstract_t">Kiss EE, Alex G, Chandran N, Olomu P. Anesthetic implications of a pediatric patient with stiff skin syndrome: A case report. Paediatr Anaesth 2020; 30:1149.</a></li><li><a class="nounderline abstract_t">Jablonska S, Blaszczyk M. Scleroderma-like indurations involving fascias: an abortive form of congenital fascial dystrophy (Stiff skin syndrome). Pediatr Dermatol 2000; 17:105.</a></li><li><a class="nounderline abstract_t">Sanchez-Espino LF, Sibbald C, Stimec J, et al. Characteristics and onset of presentation of pediatric stiff skin syndrome: A retrospective cohort study of 11 patients in a tertiary care center. Pediatr Dermatol 2024; 41:16.</a></li><li><a class="nounderline abstract_t">Wen X, Chen F, Wang L. Stiff skin syndrome: a clinicopathological study of 31 cases. Eur J Dermatol 2023; 33:235.</a></li><li><a class="nounderline abstract_t">McCalmont TH, Gilliam AE. A subcutaneous lattice-like array of thick collagen is a clue to the diagnosis of stiff skin syndrome. J Cutan Pathol 2012; 39:2.</a></li><li><a class="nounderline abstract_t">Ko CJ, Atzmony L, Lim Y, et al. Review of genodermatoses with characteristic histopathology and potential diagnostic delay. J Cutan Pathol 2019; 46:756.</a></li><li><a class="nounderline abstract_t">Pinal-Fernandez I, Selva-O' Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 2014; 13:379.</a></li><li><a class="nounderline abstract_t">Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64:217.</a></li><li><a class="nounderline abstract_t">Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011; 64:231.</a></li><li class="breakAll">Shieh JT, Hoyme HE, Arbour LT. Hyaline fibromatosis syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li><a class="nounderline abstract_t">McKenna T, Sola Carvajal A, Eriksson M. Skin Disease in Laminopathy-Associated Premature Aging. J Invest Dermatol 2015; 135:2577.</a></li><li class="breakAll">Li SC, Pope E. Localized scleroderma. In: Textbook of Pediatric Rheumatology, 7th ed, Petty R, Laxer R, Lindsley C, Wedderburn L (Eds), Elsevier Saunders, 2016. p.406.</li><li><a class="nounderline abstract_t">Maillet-Lebel N, Kokta V, Coulombe J, Powell J. A case of segmental stiff skin syndrome treated with systemic losartan. Pediatr Dermatol 2018; 35:e66.</a></li><li><a class="nounderline abstract_t">Kurtzman DJ, Wright NA, Patel M, Vleugels RA. Segmental stiff skin syndrome (SSS): Two additional cases with a positive response to mycophenolate mofetil and physical therapy. J Am Acad Dermatol 2016; 75:e237.</a></li><li><a class="nounderline abstract_t">Quintana Castanedo L, Rodríguez Bandera AI, Feito Rodríguez M, et al. Clinical presentation, sonographic features and treatment options of segmental stiff skin syndrome. Clin Exp Dermatol 2021; 46:135.</a></li><li><a class="nounderline abstract_t">Ogunmakin K, Vangipuram R, Sturgeon A, Shimizu I. A 7-year-old with indurated skin and unilateral progressive joint immobility: A case of stiff skin syndrome. Dermatol Online J 2015; 21.</a></li><li><a class="nounderline abstract_t">Chiu HH, Wu MH, Wang JK, et al. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc 2013; 88:271.</a></li><li><a class="nounderline abstract_t">Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013; 34:3491.</a></li><li><a class="nounderline abstract_t">Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med 2014; 371:2061.</a></li><li><a class="nounderline abstract_t">Roos N, Poulalhon N, Farge D, et al. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007; 321:583.</a></li><li><a class="nounderline abstract_t">Gelinas A, Powell J, Lapointe C, Coulombe J. Segmental stiff skin syndrome treated with secukinumab. Pediatr Dermatol 2023; 40:738.</a></li></ol></div><div id="topicVersionRevision">Topic 119593 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5100776" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Stiff skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26944597" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Segmental stiff skin syndrome (SSS): A distinct clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33769553" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Segmental stiff skin syndrome (SSS): Clinical case and a brief review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30874234" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Middle-Aged Female Diagnosed With Widespread Stiff Skin Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375004" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979247" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A microfibril assembly assay identifies different mechanisms of dominance underlying Marfan syndrome, stiff skin syndrome and acromelic dysplasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32698527" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pro-Fibrotic Phenotype in a Patient with Segmental Stiff Skin Syndrome via TGF-βSignaling Overactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31640988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A disease-associated mutation in fibrillin-1 differentially regulates integrin-mediated cell adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32212274" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Segmental stiff skin syndrome: a novel case with an interleukin-17C mutation successfully treated with secukinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936399" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2808830" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Congenital fascial dystrophy: stiff skin syndrome--a human counterpart of the tight-skin mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37115944" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic Exertional Compartment Syndrome Requiring Bilateral Fasciotomy: An Atypical Complication of Familial Stiff Skin Syndrome in a Father and Son.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32761718" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Anesthetic implications of a pediatric patient with stiff skin syndrome: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792797" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Scleroderma-like indurations involving fascias: an abortive form of congenital fascial dystrophy (Stiff skin syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37864376" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Characteristics and onset of presentation of pediatric stiff skin syndrome: A retrospective cohort study of 11 patients in a tertiary care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37594328" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Stiff skin syndrome: a clinicopathological study of 31 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22211327" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A subcutaneous lattice-like array of thick collagen is a clue to the diagnosis of stiff skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31148225" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Review of genodermatoses with characteristic histopathology and potential diagnostic delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424187" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnosis and classification of eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21238823" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21238824" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Update on morphea: part II. Outcome measures and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21238824" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Update on morphea: part II. Outcome measures and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26290387" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Skin Disease in Laminopathy-Associated Premature Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26290387" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Skin Disease in Laminopathy-Associated Premature Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29110325" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A case of segmental stiff skin syndrome treated with systemic losartan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27846975" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Segmental stiff skin syndrome (SSS): Two additional cases with a positive response to mycophenolate mofetil and physical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32697852" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical presentation, sonographic features and treatment options of segmental stiff skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26437281" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A 7-year-old with indurated skin and unilateral progressive joint immobility: A case of stiff skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23321647" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Losartan added toβ-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999449" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25405392" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Atenolol versus losartan in children and young adults with Marfan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17272676" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36825671" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Segmental stiff skin syndrome treated with secukinumab.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
